HC Wainwright & Co. Assumes Eton Pharmaceuticals at Buy, Announces Price Target of $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has assumed coverage of Eton Pharmaceuticals with a Buy rating and set a price target of $9.
September 04, 2024 | 10:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has assumed coverage of Eton Pharmaceuticals with a Buy rating and set a price target of $9, indicating a positive outlook.
The Buy rating and $9 price target from HC Wainwright & Co. suggest a positive outlook for Eton Pharmaceuticals, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100